Download PDF
Horm Metab Res 1998; 30(3): 150-152
DOI: 10.1055/s-2007-978855
Originals Clinical

© Georg Thieme Verlag Stuttgart · New York

Vanadyl Treatment Normalizes Submandibular Salivary Gland Insulin-Like Immunoreactivity in Streptozotocin-Diabetic Rats

D. Deville de Périère1 , P. Poucheret2 , J.-C. Egea1 , R. Gross3 , P. Masiello1 ,*, G. Cros2 , J. J. Serrano2 , G. Ribes3
  • 1Laboratoire de Physiologie. Faculté d'Odontologie. B. P. 4305 Montpellier, France
  • 2Laboratoire de Pharmacologie. Faculté de Pharmacie. 34060 - Montpellier Cedex 01, France
  • 3Laboratoire de Pharmacologie. Faculté de Médecine. UMR - CNRS 9921, 34060 - Montpellier Cedex 01, France
* on leave from Istituto Patologia Generale, University of Pisa, Italy
Further Information

Publication History

1996

1997

Publication Date:
20 April 2007 (online)

Also available at
  PDF Download  Permissions and Reprints

Rat submandibular salivary glands (SSG) contain a compound displaying insulin-like immunoreactivity (ILI) and various biological activities of insulin. As SSG ILI levels were reported to be increased in streptozotocin (STZ)-induced diabetes but not normalized by a two-week insulin treatment, we decided to check whether another antidiabetic treatment, vanadyl sulphate (VOSO4), was able to regulate SSG ILI concentration. A short term (8 days) i.p. VOSO4 treatment (total dose = 1.3 mmol/kg) of rats made diabetic 8 days earlier by a single i.v. injection of STZ (60 mg/kg BW) was able to induce a long-term (4 weeks) correction of hyperglycemia while weight gain was re-established. In untreated diabetic animals (≈ - 25%) and increased (≈ + 175%) as compared to normal rats. Both parameters were normalized in VOSO4-treated diabetic rats.

Key words

Insulin-like Immunoreactivity - Submandibular Salivary Gland - Diabetes - Rat - Vanadyl